Fabry Disease – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fabry
Disease – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Fabry Disease – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Fabry Disease (Genetic Disorders), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Fabry Disease (Genetic Disorders) pipeline guide also reviews key
players involved in therapeutic development for Fabry Disease and
features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and
Preclinical stages are 1, 2, 3, 1, 1 and 9 respectively. Similarly, the
Universities portfolio in Unknown stages comprises 1 molecules,
respectively.

Fabry Disease (Genetic Disorders) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Fabry Disease (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Fabry Disease
  (Genetic Disorders) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Fabry Disease
  (Genetic Disorders) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Fabry Disease (Genetic Disorders)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Fabry Disease (Genetic Disorders).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Fabry Disease (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Fabry Disease (Genetic Disorders) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Abeona Therapeutics Inc.
• Amicus Therapeutics Inc.
• AVROBIO Inc.
• Biosidus S.A.
• Chiesi Farmaceutici S.p.A.
• Freeline Therapeutics Ltd.
• Genzyme Corp.
• Greenovation Biotech GmbH
• iBio Inc.
• Idorsia Pharmaceutical Ltd.
• Moderna Therapeutics Inc.
• Pharming Group N.V.
• Resverlogix Corp.
• Sangamo Therapeutics Inc.
• UniQure N.V.

Key Topics Covered

1. Introduction
2. Overview
3. Therapeutics Development
4. Therapeutics Assessment
5. Companies Involved in Therapeutics Development
6. Dormant Projects
7. Discontinued Products
8. Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/k0rxmk

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs